+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Phase 3
Age: 18Years +
All Genders
Healthy Volunteers
ID07184684

Study of Nasal Microbiome Transplants to Treat Chronic Rhinosinusitis With or Without Nasal Polyps in Adults A Double-Blind Placebo-Controlled Cross-Over Trial

Led by Region Skane · Updated on 2025-09-22

50

Participants Needed

1

Research Sites

156 weeks

Total Duration

AI-Summary

What This Trial Is About

Chronic rhinosinusitis CRS is a condition that negatively affects quality of life and carries significant societal costs. The cause of CRS is not fully understood, and current treatments are based on observed effects rather than a clear understanding of the disease mechanisms. CRS is divided into types based on the presence of nasal polyps, and recent research suggests that differences in the inflammatory profile, or endotype, are important for studying the disease. This trial explores the role of the nasal microbiome in CRS, following previous findings that microbiome transplants may reduce symptoms in patients without nasal polyps. Participants in this study will receive 13 days of antibiotics followed by either five consecutive days of a sinonasal microbiome transplant from a healthy donor or five days of a placebo saline transplant administered as nasal lavage. The study uses a double-blind, placebo-controlled, crossover design to compare these treatments. The transplant aims to restore a healthy nasal microbiome, and the study will analyze differences in microbiome structure, stability, and function between CRS patients and healthy donors. During the study, participants will be evaluated before and after the interventions using several assessments including the Sino-Nasal Outcome Test 22 SNOT-22, endoscopy, nasal symptom scores, and analyses of microbiome and inflammatory markers. These evaluations will take place at multiple time points up to three years after the study to monitor symptom changes, microbiome effects, and safety. The total study duration is one year and five months, with an additional three years of follow-up for long-term outcomes.

CONDITIONS

Brief Title

Sinonasal Microbiome Transplant as a Therapy for Chronic Rhinosinusitis (CRS).

Research Team

A

Anders Mårtensson, MD, PhD

F

Frida Blixt, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here